Skip to main content
BRAIN Biotech AG logo

BRAIN Biotech AG — Investor Relations & Filings

Ticker · BNN ISIN · DE0005203947 LEI · 391200JKPVHLD6JLZ107 F Professional, scientific and technical activities
Open in API
Filings indexed 368 across all filing types
Latest filing 2017-09-19 Declaration of Voting R…
Country DE Germany
Listing F BNN

About BRAIN Biotech AG

https://www.brain-biotech.com/

BRAIN Biotech AG is an industrial biotechnology company specializing in the discovery, development, and production of specialty enzymes, high-performance microorganisms, and bioactive compounds. The company provides tailor-made biosolutions and contract research and development (R&D) services to partners in the food, chemical, and life sciences sectors. Core competencies include enzyme technology, microbial strain development, and bioprocess development. By leveraging an advanced technology portfolio, which includes proprietary platforms for enzyme discovery and genome editing, the company enables its partners to create more sustainable and efficient industrial products and processes, contributing to the bioeconomy.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2017
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables regarding the 'Notification of Major Holdings' under German securities law (WpHG). It specifies the date a threshold was crossed (15 Sep 2017) and details the resulting percentage of voting rights held by an individual and associated entities. This directly corresponds to the definition of a Major Shareholding Notification, which tracks changes in significant ownership levels crossing regulatory thresholds.
2017-09-19 English
B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN AG wins new long-term oriented investor by way of a capital increase
Share Issue/Capital Change Classification · 99% confidence The document is a news release announcing that BRAIN AG successfully implemented a capital increase by issuing new shares to a new investor. Key phrases include 'capital increase', 'Proceeds from capital increase planned to be used for new acquisitions', and the announcement format typical of corporate news disseminated via services like DGAP. This event directly relates to changes in the company's capital structure and fundraising activities. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). It is not a full 10-K, an ER (which focuses on operational results), or a simple RPA/RNS, as it details a specific financing transaction.
2017-09-07 English
B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN AG resolves upon capital increase - new long-term investor subscribes all new shares
Capital/Financing Update Classification · 99% confidence The document is an Ad-hoc announcement dated September 7, 2017, detailing that BRAIN AG resolved upon a capital increase of approximately 10% through a private placement, excluding shareholder subscription rights. The key terms used are 'capital increase', 'new shares', 'private placement', and 'shareholders’ subscription rights have been excluded'. This directly relates to changes in the company's capital structure and fundraising activities. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV).
2017-09-07 English
B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN achieves notable top- and bottom-line improvements in the first nine months 2016/17
Earnings Release Classification · 100% confidence The document is a news release dated August 31, 2017, titled "BRAIN achieves notable top- and bottom-line improvements in the first nine months 2016/17." It explicitly states that the company "today published its financial results for the first nine months of fiscal year 2016/17." It provides key financial highlights, segment performance, and comparative figures for the nine-month period. This content aligns perfectly with the definition of an Earnings Release (ER), which is the initial announcement of periodical financial results, often containing key highlights before a more comprehensive report (like an IR) is filed. Although it mentions a link to the 'quarterly statement,' the document itself is the announcement of those results, making ER the most appropriate classification over IR (Interim Report) or RPA (Report Publication Announcement), given the level of detail provided. 9M 2017
2017-08-31 English
Q3 statement / Q3 financial report 2016/2017
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Statement' for the period ending 30 June 2017. It contains comprehensive financial data, including a consolidated income statement, balance sheet, cash flow statement, and notes to the financial statements. It is not an earnings release (which would be shorter and highlight-focused) nor an annual report (10-K). It fits the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data for a period shorter than a full fiscal year. Q2 2017
2017-08-31 German
B.R.A.I.N. Biotechnology Research And Information Network AG: Strong demand for BRAIN shares from institutional investors
Major Shareholding Notification Classification · 99% confidence The document is a press release dated August 29, 2017, announcing a significant transaction involving the sale of shares by one shareholder (Green Industries Group GmbH & Co. KG) and the acquisition of a portion of those shares by another major shareholder (MP Beteiligungs-GmbH). This transaction directly impacts the free float and ownership structure of the company's stock. This type of announcement, detailing changes in significant share ownership or insider/major shareholder transactions that affect the public float, aligns best with the 'Major Shareholding Notification' (MRQ) or potentially 'Director's Dealing' (DIRS) if the selling party were a director, but since it concerns a major shareholder group's portfolio adjustment leading to an increased free float, MRQ is the most appropriate fit among the provided options, as it relates to changes in significant share ownership levels crossing thresholds or major structural shifts in holdings. It is not an earnings release, a capital raise, or a proxy statement. Given the focus on the change in shareholding structure and free float, MRQ is selected.
2017-08-29 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.